Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C44H60FN3O10.H2O |
| Molecular Weight | 827.975 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.COC1=CC=C(C=C1)[C@@H]2[C@@H](CC[C@H](O)C3=CC=C(F)C=C3)C(=O)N2C4=CC=C(CNC(=O)CCCCCCCCCCC(=O)NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C=C4
InChI
InChIKey=JEXPSLMKZGKTRB-WQJVVCBDSA-N
InChI=1S/C44H60FN3O10.H2O/c1-58-34-22-16-31(17-23-34)41-35(24-25-36(50)30-14-18-32(45)19-15-30)44(57)48(41)33-20-12-29(13-21-33)26-46-39(53)10-8-6-4-2-3-5-7-9-11-40(54)47-27-37(51)42(55)43(56)38(52)28-49;/h12-23,35-38,41-43,49-52,55-56H,2-11,24-28H2,1H3,(H,46,53)(H,47,54);1H2/t35-,36+,37+,38-,41-,42-,43-;/m1./s1
Canosimibe is diphenyl azetidinone patented by German pharmaceutical company Aventis Pharma Deutschland GmbH as hypolipidemic agent. Canosimibe acts as pre-systemic inhibition of intestinal cholesterol absorption. Unfortunately, during phase II clinical trials Canosimibe failed to demonstrate efficacy in in patients with primary severe hypercholesterolemia.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
171390178
Created by
admin on Wed Apr 02 19:40:00 GMT 2025 , Edited by admin on Wed Apr 02 19:40:00 GMT 2025
|
PRIMARY | |||
|
E82K2PRL5G
Created by
admin on Wed Apr 02 19:40:00 GMT 2025 , Edited by admin on Wed Apr 02 19:40:00 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
